# Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

> **NCT01047072** · PHASE2 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium**

## Conditions studied

- Systemic Scleroderma

## Interventions

- **DRUG:** fludarabine phosphate
- **RADIATION:** total-body irradiation
- **DRUG:** tacrolimus
- **DRUG:** mycophenolate mofetil
- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT01047072
- **Lead sponsor:** Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-09
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047072, "Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01047072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*